Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
09 juil. 2020 07h30 HE
|
Kitov Pharma Ltd.
Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer ...
Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody
08 juil. 2020 07h30 HE
|
Kitov Pharma Ltd.
Patent coverage for CM24 now extends to the U.S. and the EU TEL AVIV, Israel, July 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company...
Kitov Pharma Issues CEO Shareholder Letter Providing Business Update
02 juil. 2020 08h34 HE
|
Kitov Pharma Ltd.
• Emerging oncology pipeline continues to advance• Strong balance sheet with over $60M in cash TEL AVIV, July 02, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE:...
Kitov Closes $35.0 Million Registered Direct Offering
25 juin 2020 16h30 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Announces $35.0 Million Registered Direct Offering
23 juin 2020 13h20 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, June 23, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients
22 mai 2020 07h00 HE
|
Kitov Pharma Ltd.
Company to Evaluate NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer in a Phase...
Kitov Announces U.S. Commercial Launch of Consensi™
20 mai 2020 07h30 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, May 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II
19 mai 2020 08h05 HE
|
Kitov Pharma Ltd.
Company Expects to Initiate Phase 1/2 Trial of NT-219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head...
Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific Program
14 mai 2020 07h10 HE
|
Kitov Pharma Ltd.
Company Expects to Initiate Phase 1/2 Clinical trial, in Collaboration with Bristol Myers Squibb, with CM-24 in Combination with nivolumab (Opdivo®) in Second Half of 2020 TEL AVIV, Israel, May...
Kitov Closes $10 Million Registered Direct Offering
08 mai 2020 16h00 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...